

Building Blocks for Solid-phase Glycopeptide Synthesis: 2-Acetamido-2-deoxy- β -D-glycosides of FmocSerOH and FmocThrOH

Gemma Arsequell,* Lorely Krippner, Raymond A. Dwek and Simon Y. C. Wong

Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK OX1 3QU

A convenient and optimized synthesis of 2-acetamido-2-deoxy- β -D-glycosides of FmocSerOH and FmocThrOH, building blocks for solid-phase synthesis of glycopeptides containing GlcNAc β -linked to Ser or Thr, is for the first time established.

2-Acetamido-2-deoxy- β -D-glycosides widely exist as important fragments of peptidoglycans, glycoproteins, mucopolysaccharides, and blood group determinants. Recently, a major new form¹ of protein glycosylation (termed *O*-GlcNAc) that is found in all eukaryotes has been described. *O*-GlcNAc is a simple, unmodified monosaccharide moiety β -glycosidically linked to the side-chain hydroxyls of serine or threonine. The natural occurrence of such *N*-acetylglucosamine glycosides has stimulated efforts towards the development of glycosylation reactions using D-glucosamine derivatives.²

Few routes have been found for the synthesis of 2-acetamido-2-deoxy- β -D-glycosides of Ser or Thr having a β conformation. Traditional Koenigs–Knorr³ type reaction is one of the desired processes for the synthesis of glucosamine glycosides. In these cases, 2-acetamido-2-deoxy-3,4,6-tri-*O*-acetyl- α -D-glucopyranosyl halides (Cl, F) are always used as glycosyl donors⁴ and both amino and carboxy protected Ser and Thr as glycosyl acceptors. However, problems associated with Koenigs–Knorr reactions are instability of the glycosyl halides, poor yields, synthesis of mixtures of α and β anomers, difficult deprotection of the amino function, toxic character of the promoters, and the necessity of several steps to obtain the desired glycosides.

Another major process for the synthesis of glucosamine glycosides is the acid catalysed reaction of oxazoline derivatives.⁵ The oxazoline procedure, an extension of Koenigs–Knorr glycosylation method, and its various improvements, allowed the successful synthesis of 1,2-*trans*-2-acetamido-2-deoxy glycosides and oligosaccharides. The most commonly used sugar oxazolines⁶ are the methyl oxazolines. These are reactive intermediates upon activation by an acid⁷ or Lewis acids⁸ will allow nucleophilic attack by a glycosyl acceptor to afford anomerically pure β -glycosides possessing the natural *N*-acetyl function, which is an extremely useful feature.

With the aim to establish a new reliable procedure for the synthesis of suitable 2-acetamido-2-deoxy-glycosides of amino acids for solid-phase peptide synthesis (SPPS), the latter approach was optimized for the 'one pot' synthesis of the two building blocks **2** and **3**, respectively (Scheme 1). The present pathway makes use of three better and convenient features. First the use of *N*^α-Fmoc⁹ for the protection of the amino

function eliminates the requirement of acidic conditions, to which the *O*-glycosidic linkage is sensitive, for deprotection. *N*^α-Fmoc, unlike Boc or Z groups, is labile to mild organic bases¹⁰ such as morpholine or piperidine without β -elimination. Second the *O*-acetyl groups for the hydroxy groups of the carbohydrate moiety can be easily removed with sodium methoxide in methanol.¹¹ Third the α -carboxyl group of the amino acid remains free as in Eloffson's approach.¹²

The oxazoline of the readily available 2-acetamido-2-deoxy-1,3,4,6-tetra-*O*-acetyl- β -D-glucopyranose **1** is prepared using an excess (3 equiv.) of boron trifluoride etherate as Lewis acid promoter. This is the glycosyl donor for the *in situ* glycosylation of the hydroxy groups of the commercially available, FmocSerOH and FmocThrOH.† The β -D-configuration of the glycosidic bond was established from the NMR spectrum‡ by the high value of the coupling constant for the anomeric proton (H-1) of $J_{1,2} = 8.4$ Hz. No α -linked products were detected. The building block **2** has been successfully employed in the solid-phase peptide synthesis of an *O*-glycosylated nonapeptide fragment analogue of the Sendai virus nucleoprotein^{324–332} wildtype: K3-*O*-GlcNAc¹³ [FAPS(*O*- β -GlcNAc)NYPAL].


G. A. gratefully acknowledges a Fleming postdoctoral fellowship (Ministry of Education and Science and The British Council, Spain).

Received, 8th July 1994; Com. 4/04181J

Footnotes

† FmocSer (β -D-pGlcNAc)OH **2** was prepared as follows: 240 mg (0.616 mmol) of peracetylated GlcNAc **1** was placed under an argon atmosphere in a flask containing 4 Å molecular sieves and CH₂Cl₂ (4 ml) was added. After cooling to 0 °C, 200 μ l (1.91 mmol, 3.1 equiv.) of freshly distilled BF₃·Et₂O are added dropwise to the suspension. After overnight stirring at room temperature the formation of the oxazoline was complete as monitored by TLC (CHCl₃–MeOH 10:1). Then 80 μ l (0.574 mmol) of Et₃N are added dropwise at 0 °C. The reaction mixture was left stirring for 10 min and a solution of 208 mg (0.635 mmol) of FmocSerOH, in a mixture of CH₂Cl₂–acetonitrile (2:1) was added. The reaction mixture was left to stand at room temperature and periodically monitored by TLC (CHCl₃–MeOH–AcOH 80:10:1) and RP-HPLC (Merck 50983, Lichrospher 100 RP-18, 5 μ m, 70–20% of MeCN–H₂O with 0.1% TFA in 30 min). To further enhance the yield a second batch of oxazoline (240 mg, 0.616 mmol) prepared in the same way as described above may be added after 24 h. When the reaction was complete, (from 48–150 h), the crude was neutralized at 0 °C with Et₃N, diluted with CH₂Cl₂ and filtered through Celite. The filtrate was concentrated and the crude purified by column chromatography (silica gel, CHCl₃–MeOH from 30:1 to 10:1). Following purification, FmocSer(β -D-pGlcNAc)OH **2** was obtained in a 55% yield. This reaction has been scaled up to a 1 g (2.5 mmol) of peracetylated GlcNAc. A similar procedure was followed for the synthesis of FmocThr(β -D-pGlcNAc)OH **3** which was obtained in a 53% yield.

‡ Selected data FmocSer (β -pGlcNAc)OH **2**: α ²²_D = +27.8 (*c* = 1, MeOH); 500 MHz ¹H NMR: δ ([²H₆]DMSO = 2.49 at 300 K): 1.74 (s, 3H, NHCOCH₃); 1.92, 1.98, 2.02 (s, 9H, COCH₃); 4.73, 8.4 (d, 1H, H-1). 125.7 MHz ¹³C NMR: δ ([²H₆]DMSO = 39.5 at 300 K): 20.32, 20.36, 20.45 (CH₃–CO); 22.53 (NH–COCH₃); 100.36 (C-1); 155.63 (NHCO₂). ESMS: *m/z* 701.3 (M + 2 Na). FmocThr (β -pGlcNAc)OH **3**: α ²²_D = +14.7 (*c* = 1, MeOH); 500 MHz ¹H NMR: δ ([²H₆]DMSO = 2.49 at 300 K): 1.13, 7.0 (d, 3H, Thr-CH₃); 1.79 (s,



Scheme 1 Reagents and conditions: i, BF₃·Et₂O (3 equiv.), CH₂Cl₂, 0 °C, then Et₃N (1 equiv.); ii, FmocSerOH (R = H) or FmocThrOH (R = Me), (1 equiv.), CH₂Cl₂–MeCN

3H, NHCOCH₃); 1.94, 1.98, 1.99 (s, 9H, COCH₃); 4.78, 8.5 (d, 1H, H-1). 125.7 MHz ¹³C NMR; δ ([²H₆]DMSO = 39.5 at 300 K): 17.44 (Thr-CH₃); 98.45 (C-1); 156.01 (NHCO₂). ESMS: *m/z* = 693.4 (*M* + 23).

References

- 1 R. S. Haltiwanger, W. G. Kelly, E. P. Roquemore, M. A. Blomberg, L. Y. Dennis Dong, L. Kreppel, T. Y. Chou and G. W. Hart, *Biochem. Soc. Trans.*, 1992, **20**, 264.
- 2 Review: P. Boullanger and D. Lafont, *Chem. Rev.*, 1992, **92**, 1167.
- 3 W. Koenigs and E. Knorr, *Ber.*, 1901, **34**, 957.
- 4 (a) D. J. Walton, J. K. N. Jones, M. B. Perry, B. Shelton and D. J. Walton, *Can. J. Chem.*, 1961, **39**, 1005; (b) E. Werries and E. Buddecke, *Hoppe-Seyler's Z. Physiol. Chem.*, 1970, **351**, 1089; (c) M. G. Vafina, A. Kim and N. Molodtsov, *Carbohydr. Res.*, 1978, **64**, 334; (d) S. Lavielle, N. C. Ling, R. Saltman and R. C. Guillemin, *Carbohydr. Res.*, 1981, **89**, 229; (e) H. G. Garg and R. W. Jeanloz, *Carbohydr. Res.*, 1976, **49**, 482; (f) K. Wakabashi and W. Pigman, *Carbohydr. Res.*, 1974, **35**, 3.
- 5 Reviews on oxazolines: W. P. Stöckl and H. Weidmann, *J. Carbohydr. Chem.*, 1989, **8**, 169; T. G. Gant and A. I. Meyers, *Tetrahedron Report No. 30*, 1994, **50**, 2297.
- 6 S. Nakabayashi, C. D. Warren and R. W. Jeanloz, *Carbohydr. Res.*, 1986, **150**, C7; S. E. Zurabyan, T. P. Volosyuk and A. J. Khorlin, *Carbohydr. Res.*, 1969, **9**, 215.
- 7 With *p*-TsOH: J. C. Jacquinet, S. E. Zurabyan and A. Ya. Khorlin, *Carbohydr. Res.*, 1974, **32**, 137; ref 4c and e.
- 8 With TMSOTf: M. Hollosi, E. Kollat, I. Laczko, K. F. Medzih-radszky, J. Thurin and L. Otvös, Jr., *Tetrahedron Lett.*, 1991, **32**, 1531; P. C. Boldt, M. H. M. G. Schumacher-Wandersleb and M. G. Peter, *Tetrahedron Lett.*, 1991, **32**, 1413. With FeCl₃ anh.: M. Kiso and L. Anderson, *Carbohydr. Res.*, 1979, **72**, C12.
- 9 L. A. Carpino and G. Y. Chan, *J. Org. Chem.*, 1972, **37**, 3404.
- 10 H. Paulsen and J. P. Hölek, *Carbohydr. Res.*, 1982, **109**, 89; J. Kihlberg and T. Vuljanic, *Tetrahedron Lett.*, 1993, **34**, 6135.
- 11 B. Lünig, T. Norberg and J. Tejbrant, *J. Chem. Soc., Chem. Commun.*, 1989, 1267.
- 12 M. Elofsson, B. Walse and J. Kihlberg, *Tetrahedron Lett.*, 1991, **32**, 7613.
- 13 G. Arsequell, A. C. Lellouch, S. Y. C. Wong, J. S. Haurum, T. Elliott and R. A. Dwek, manuscript in preparation.